Der sås en stigning i mortalitet i ELITE II i den lille undergruppe (22% af alle HF- patienter), der tog beta- blokkere ved baseline.
An increased mortality was observed in ELITE II in the small subgroup (22% of all HF patients) taking beta-blockers at baseline.